Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Twist Bioscience Corp (TWST) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance

Twist Bioscience CorpTrade
Consumer Staples Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Twist Bioscience Corp vs Consumer Staples Select Sector SPDR Fund — how do they compare? Twist Bioscience Corp trades at $165.14 (market cap $10.08B), while Consumer Staples Select Sector SPDR Fund trades at $83.24 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.

TWSTXLP
Market Cap
$10.08B$13.50B
Volume
4,229,03714,599,953
Sector
Health—
52-Week High
$205.00$90.00
52-Week Low
$25.45$75.61
Typical Hold Time
27 Days72 Days
Enterprise Value
$10.01B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Twist Bioscience Corp

TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.

The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.

Consumer Staples Select Sector SPDR Fund

XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.21, up 1.85% with bullish technical signals from moving averages and oscillators. The ETF has gained 6.6% year-to-date, outperforming consumer discretionary stocks. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peers.

The outlook remains favorable given XLP's defensive positioning in consumer staples, though rising interest rates pose a headwind. Investment opportunity lies in the ETF's stability during market volatility, while risks include persistent inflation pressures and potential consumer spending slowdown. The technical setup suggests continued upward momentum with support at $82-83 levels.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TWST
37% Buy63% Sell
Avg holding period · 27 Days
XLP
100% Buy0% Sell
Avg holding period · 72 Days

Top news

Latest headlines on both assets

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →

About Consumer Staples Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.

Read more on XLP →